Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;54(2):337-341.
doi: 10.1111/imj.16316.

Clinician perceptions of research priorities for the management of noncritically ill patients admitted to hospital with SARS-CoV-2 infection

Methma M Bandara  1 , Lauren A Barina  1 , Grace M McPhee  1 , Susan R Goulding  1 , Justin T Denholm  1   2 , Susan C Morpeth  3   4 , Steven Y C Tong  1   2 ; ASCOT Group
Collaborators, Affiliations

Clinician perceptions of research priorities for the management of noncritically ill patients admitted to hospital with SARS-CoV-2 infection

Methma M Bandara et al. Intern Med J. 2024 Feb.

Abstract

The changing phenotype of coronarvirus disease 2019 (COVID-19) may quickly render guideline-recommended interventions obsolete. We developed a 40-question clinician survey in consultation with the Australasian COVID-19 Trial site investigators. The survey was designed to assess clinician perceptions of the current treatment strategies and future research priorities in the management of non-critically ill patients admitted to hospital with SARS-CoV-2 infection. There were 84 complete responses from predominantly Australian and New Zealand clinicians. The perceived prevalence of patients with incidental COVID-19, nosocomial infection, underlying illness exacerbated by COVID-19, and/or immunocompromised status suggests new populations to target. The results highlighted clinician interest in antiviral therapies for future research in both immunocompetent and immunocompromised cohorts. These survey results underscore the need for ongoing surveillance of COVID-19 disease phenotypes and clinician and patient priorities for future research.

Keywords: COVID-19; antivirals; immunocompromised; treatment.

PubMed Disclaimer

References

    1. WHO Coronavirus (COVID-19) Dashboard. World Health Organization; [Cited 2023]. Available from URL: https://covid19.who.int/
    1. Nab L, Parker EPK, Andrews CD, Hulme WJ, Fisher L, Morley J et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health 2023; 8: e364-e377.
    1. Ellis RJ, Moffatt CR, Aaron LT, Beaverson G, Chaw K, Curtis C et al. Factors associated with hospitalisations and deaths of residential aged care residents with COVID-19 during the Omicron (BA.1) wave in Queensland. Med J Aust 2023; 218: 174-179.
    1. Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg Health Am 2023; 20: 100461.
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med 2020; 383: 1813-1826.

Publication types

LinkOut - more resources